Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus fermentum 338-1-1
- Development stage
- Unknown
- Lead developer
- University of Tartu
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus fermentum 338-1-1 is a candidate probiotic bacterial strain investigated for its potential application in biodefense and the enhancement of passive immunity. Developed by researchers at the University of Tartu with support from the Estonian Science Foundation, the strain was evaluated in a Phase 1 clinical trial to assess its safety, tolerability, and persistence in the human gastrointestinal tract following oral administration. The strain is intended to bolster the host's biological defenses against bioterrorism agents, such as *Bacillus anthracis*, through mechanisms including competitive exclusion of pathogens and modulation of the mucosal immune response. As a live biotherapeutic product, it aims to provide a non-specific protective barrier and enhance the body's natural resistance to infection.
- Other names
- L. fermentum 338-1-1
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on Lactobacillus fermentum 338-1-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus fermentum 338-1-1.